


Cite this: *RSC Adv.*, 2024, 14, 1710

# Pyrrolo[2,1-*a*]isoquinoline scaffolds for developing anti-cancer agents

Leidy J. García Maza,<sup>a</sup> Arturo Mendoza Salgado,<sup>a</sup> Vladimir V. Kouznetsov<sup>b</sup> and Carlos M. Meléndez<sup>a\*</sup>

Fused pyrrolo[2,1-*a*]isoquinolines have emerged as compelling molecules with remarkably potent cytotoxic activity and topoisomerase inhibitors. This comprehensive review delves into the intricate world of this family of compounds, analyzing the natural marine lamellarins known for their diverse and complex chemical structures, exploring structure–activity relationships (SARs), and highlighting their remarkable versatility. The review emphasizes their fundamental role as topoisomerase inhibitors and cytotoxic agents, as well as some crucial aspects of the chemistry of pyrrolo[2,1-*a*]isoquinolines, exploring synthetic strategies in total synthesis and molecular diversification trends, highlighting their importance in the field of medicinal chemistry and beyond.

Received 16th October 2023  
Accepted 14th December 2023

DOI: 10.1039/d3ra07047f

rsc.li/rsc-advances

## Introduction

Natural products from plants and marine organisms have become a hotspot of research over the past thirty-five years due to their remarkable capacity to produce diverse, complex chemical substances.<sup>1</sup> Marine alkaloids called lamellarins are among the most promising families of natural marine products with various biological properties. As a result, there has been a growing interest in this alkaloid family, the bio-origin of which starts with 2-amino-3-(3',4'-dihydroxyphenyl)propionic acid, known as DOPA.<sup>2</sup> These DOPA-derived marine pyrrole alkaloids have been extensively studied.<sup>3</sup> Since the discovery of the first lamellarins A–D in 1985, more than 70 lamellarins and their natural and synthetic analogs have been isolated and described to date.<sup>4</sup> Having a pyrrolo[2,1-*a*]isoquinoline scaffold, the lamellarins and related alkaloids (lukianols, polycitrins, storniamides, and ningalins) exhibit a wide range of biological activities, including cytotoxicity against tumor cells, anti-cancer activity, multi-drug resistance reversal activity, and antibiotic and antioxidant properties, making these compounds a singularly important subject for research.<sup>5</sup>

Cancer is the leading cause of death and represents a large and diverse group of diseases. The only effective therapy is chemotherapy, which frequently fails due to innate or acquired multi-drug resistance (MDR). Marine natural products represent an attractive source of bioactive chemical diversity.<sup>6</sup> Recently, target-selective lamellarin analogs have been designed, synthesized, and evaluated as anti-cancer agents. Several lamellarins have been reported to display significant

cytotoxicity, with IC<sub>50</sub> values in the submicromolar range against a range of cancer cell lines.<sup>7</sup> However, only a few showed interesting bioactive properties, whereas others (*e.g.*, lamellarins D, K, and M) are highly potent cytotoxic compounds, which have been categorized as promising lead compounds for cancer therapy in a wide variety of cancer cells due to their potent inhibition of Topoisomerase I.<sup>8,9</sup> For this reason, several efficient and versatile chemical routes to access diverse lamellarins and their pyrrolo[2,1-*a*]isoquinoline-based analogs have been portrayed.<sup>1</sup> Besides, the number of reported marine alkaloids continues to grow at an increasing rate, allowing extensive biological studies on their potential applications.<sup>10</sup>

It is already clear that DNA-manipulating enzymes constitute privileged targets for lamellarins. The Structure–Activity Relationship (SAR) studies indicated that these marine alkaloids could be considered a multi-target effector. For instance, they target Topoisomerase I (Topo-I), protein kinases (PTKs), and act on mitochondria.<sup>4</sup> Consequently, these crucial discoveries have encouraged the research community's studies on lamellarins and related alkaloids.

It is well known that various groups have provided an overview of the main achievements of lamellarin alkaloids and related pyrrole-derived alkaloids. Recently, Matveeva *et al.*<sup>11</sup> performed a detailed and rigorous analysis as much they could, of the synthetic approaches, bioactivity, mechanism of action, pharmacophore and structure–activity relationships of synthetic analogs of the pyrrolo[2,1-*a*]isoquinoline (PIq) scaffold covering 2009 to 2019. However, the progress in the synthesis and biological characterization of small molecules built up on the PIq moiety has become necessary due to great interest of modern organic chemists in pursuing efficient synthetic routes for the development of lamellarin-derived bioactive compounds. The above focused mainly on the

<sup>a</sup>Facultad de Ciencias Básicas, Grupo de Investigación de Química Orgánica y Biomédica, Universidad del Atlántico, Barranquilla, Colombia. E-mail: carlosmelendez@mail.uniatlantico.edu.co

<sup>b</sup>Laboratorio de Química Orgánica y Biomolecular, Escuela de Química, Universidad Industrial de Santander, Piedecuesta 680002, Colombia


potential exploitation of the scaffold-like pyrrolo[2,1-*a*]isoquinolines in design and development of anti-cancer agents. We present an updated and comprehensive review of lamellarins alkaloids and related pyrrole-derived alkaloids summarizing their synthesis and anti-cancer activity and providing vital information essential to developing anti-cancer compounds of this series. Additionally, the total synthesis of selected lamellarins, and advanced synthetic methods of preparing for isoquinoline and pyrrolo[2,1-*a*] isoquinoline derivatives were briefly described. Moreover, the SAR between natural lamellarin alkaloids or alkaloid-like synthetic pyrrolo[2,1-*a*]isoquinolines and cytotoxic effects was examined.

### Lamellarins and anticancer activity analysis

Lamellarins, pyrrolo[2,1-*a*]isoquinoline-based molecules (Type-I, Type-Ia and Type-Ib), and related pyrrole-derived alkaloids (Type-II) (Fig. 1) are frequently cytotoxic to a wide range of cancer cell lines, serving as a starting point in the design of anti-cancer compounds due to their interesting biological activity.<sup>12</sup> The first compounds in the series of natural products alkaloids were called lamellarins A to D, and were identified by Faulkner in 1985 from the Palauan prosobranch mollusk *Lamellaria* sp.<sup>13</sup> The lead compound in the family is lamellarin D (lam-D) (1), characterized as a potent inhibitor of both nuclear and mitochondrial Topo-I. Lam-D exhibited significant cytotoxicity




Fig. 1 Scaffolds of fused type I and non-fused type II lamellarins with potent cytotoxic activity. The compound numbers correspond to the order of appearance throughout the text.

against a large panel of cancer lines being capable of directly interfering with mitochondria to trigger cancer cell death.<sup>1</sup>

In 1993, lamellarins I, J, K, L, and M (2–5) were isolated from an Australian colonial ascidian *Didemnum* sp.<sup>14</sup> Bowden and coworkers reported that lamellarins 2–4 displayed significant cytotoxicity against P388 and A549 cell lines ( $IC_{50} \approx 0.25 \mu\text{g mL}^{-1}$  against each cell line). In 1996, Quesada and coworkers found that lamellarins 3 and 5, lamellarins D triacetate (6), K triacetate (7), and N triacetate (8) exhibited high activity against a variety of cancer cell lines (P388, AUXB1, A549, HT29, and MEL28) in the nanomolar to the sub-nanomolar range.<sup>15</sup> Lamellarins 6 and 7 showed the highest activity against the A549 cell line with  $IC_{50}$  values of 0.008 and 0.005  $\mu\text{M}$ , respectively (Fukuda, Ishibashi, and Iwao, 2020). In 1997, Faulkner *et al.* showed that lamellarin N (9) exhibited some selectivity toward the melanoma cell line SK-MEL-5 ( $LC_{50} = 0.187 \mu\text{M}$ ) and UACC-62 ( $LC_{50} = 9.88 \mu\text{M}$ ).<sup>16</sup> In 2002, Ham and Kang reported that lamellarin  $\beta$  (10) showed cytotoxicity against human promyelocytic leukemia HL-60 with an  $IC_{50} = 4.8 \mu\text{g mL}^{-1}$ .<sup>17</sup> Also, lam-I (2) at a concentration of 2  $\mu\text{M}$  could reverse the resistance of those P388 murine leukemia cells resistant to anti-cancer drugs like doxorubicin.<sup>18</sup> Furthermore, in 2010, a SAR (Structure–Activity Relationship) study on diverse lamellarins was reported.<sup>19</sup> Performed SAR studies were the first to reveal the importance of having a C-7–OH group of lamellarin core for biological activity and also confirmed that the presence of the C–C double bond (C5=C6) increased cytotoxicity; C-20- and C-8–OH groups are responsible for the cytotoxic activity and also for Topo-I inhibition while methylation of the C-7–OH- or 8–OH-groups decreased the cytotoxic activities of the lamellarins, especially those containing a C5=C6 double bond. Among the alkaloids tested, lamellarins D (1), X (11),  $\epsilon$  (12), M (5), N (9), and dehydro-lam-J (13) were the most potent anti-tumor of the family with  $IC_{50}$  values from sub-nanomolar (0.08 nM) to micromolar (3.2  $\mu\text{M}$ ) showing selectivity against cancer cells: lung, breast, liver, and blood cells.<sup>20</sup> The most promising compound was lamellarin 9.<sup>19</sup> In 2013, Yoshida and co-workers reported its synthesis and cytotoxic activity on three cancer cell lines (IMR32, HeLa, and SH-SY5Y) disclosing its high  $IC_{50}$  values (0.019–0.040  $\mu\text{M}$ ) and the Topo-I inhibitory activity which was slightly less potent than that of lam-D.<sup>21</sup>

Alkaloids lamellarin  $\chi$  (14), F (15), and lamellarin L triacetate (4) revealed excellent activities against colorectal cancer cells (COLO-205).<sup>22</sup> Besides, lamellarin H (16) and  $\alpha$  (17) exhibited good effectiveness against a panel of eight human tumor cell lines displaying mean  $IC_{50} = 4.0 \mu\text{M}$ , min/max  $IC_{50}$  ratio = 20, and mean  $IC_{50} = 2.9 \mu\text{M}$ , min/max  $IC_{50}$  ratio = 10, respectively. Lamellarins C (18) and U (19) also demonstrated potent cytotoxicity against ten human tumor cell lines (A549, HCT-116, LOX IMVI, MALME-3M, MCF-7, MOLT-4, OVCAR-3, PC-3, SF-295, UO-31) with  $IC_{50}$  ranging from 0.4 to 19.4 nM.<sup>10</sup> In 2012, the SAR studies indicted interactions between lamellarins and P-glycoprotein (P-gp), an ABC transporter efflux pump, intending to reverse multidrug resistance (MDR) in a human colon cancer cell line (SW620 Ad300). The comparative cytotoxicity of lamellarins A1, A2, and S (20–22) indicated that they could be P-gp substrates. The SAR data also suggested that the P-gp

inhibitory activity roughly correlated with higher methylation levels on rings A and F of these lamellarins. The hexamethylated lam-I (2), the only lamellarin with published data supportive of P-gp inhibitory activity, was consistent with this methylation hypothesis.<sup>7</sup>

In 1995, tri-substituted pyrrole open forms were found in the Australian marine sponge *Dendrilla cactus*, they were called lamerallin O and P.<sup>23</sup> The pyrrole ring-closed analogs of lamellarin O, such as lukianol A and lukianol B (23–25), exhibited moderate activity against a cell line derived from human epidermoid carcinoma (KB) with a minimum inhibitory concentration (MIC) of 2.4 and 185.9 nM, respectively. In addition, alkaloids 23 and 24 proved to be effective cytotoxic agents in some leukemia and lymphoma screens and also active in human HeLa–S3 uterine. Moreover, lukianol A (24) showed a selective activity against colon adenocarcinoma (SW-480) growth<sup>10</sup> and the 4'-O-dimethyl analog of lam-O identified as lamellarin O1 (26), resulted be more active ( $IC_{50} < 10 \mu\text{M}$ ) than lamellarin O (23) ( $IC_{50} > 22 \mu\text{M}$ ) against parental (SW620) and P-gp-overexpressing (SW620 Ad300) colon cancer cell lines.<sup>6,24</sup> Lately, it was found that alkaloid 23 and its 4'-O-dimethyl analog 26 act as P-gp inhibitors capable of reversing MDR.<sup>3</sup> Structure–activity relationship revealed that the methoxy-acetophenone moiety of lamellarin 23 is a critical determinant of the inhibition of the breast cancer resistance protein (BCRP). These efflux transporters, P-gp and BCRP have been implicated to be the major efflux transporters responsible for MDR in cancer cells.

Several lamellarin derivatives exhibited potent anti-cancer activities, with promising  $IC_{50}$  values. Particularly, lamellarins D (1), K (3), and M (5) are usually classified among the most cytotoxic molecules in the series.<sup>25</sup> These compounds exhibited cytotoxicity values in the nanomolar range (38–110 nM). Lam-D (1) presented a potent cytotoxic activity against a large panel of tumor cells types *in vitro*, especially in human prostate cancer cells (DU-145, LNCaP)<sup>10</sup> and at doses in the micromolar range, exhibiting high apoptotic activities in leukemia cells (K562).<sup>26</sup> Open lactone analogs of lam-D were evaluated against a panel of three human tumor cell lines, MDA-MB-231 (breast), A-549 (lung), and HT-29 (colon).<sup>27</sup> The open chain lam-D analogs data concluded that more than 75% of the tested compounds showed cytotoxicity in a low micromolar  $GI_{50}$  range. In addition, the amino derivative PM031379 (27) displayed potent anti-cancer activities *in vivo* in a human colon tumor.<sup>8</sup> Recently, Colligs demonstrated that a lam-D analog 28 with a five-membered cyclopentanone ring instead of the lactone ring (B-ring-contracted) displayed lower activity than camptothecin (CPT) in wild-type CCRF-CEM cell lines with sub-micromolar  $IC_{50}$  values.<sup>9</sup> Consequently, another important structural feature for cytotoxicity is appearing in the presence of the lactone ring (B-ring) belonging to the pentacyclic system.

A new class of antineoplastic agents was generated by attaching different glycosyl groups on hydroxy groups at C-8, C-14, or C-20 positions of lam-D. Among the glycosylated derivatives, ZL1 (29) ( $IC_{50\text{HCT116}} = 14 \text{ nM}$ ;  $IC_{50\text{HepG2}} = 24 \text{ nM}$ ) and ZL3 (30) ( $IC_{50\text{A549}} = 3 \text{ nM}$ ;  $IC_{50\text{HCT116}} = 10 \text{ nM}$ ;  $IC_{50\text{HepG2}} = 15 \text{ nM}$ ) showed potent anti-proliferation activities against all the cell lines. The cytotoxic activities of ZL1 and ZL3 were even better



than lam-D ( $IC_{50HCT116} = 25$  nM;  $IC_{50HepG2} = 88$  nM). However, the cytotoxicity of the lam-D-bearing glycosyl group at C-14-OH was decreased in the cell lines' cultures. The result demonstrated that most glycosylated derivatives kept the potent Topo-I inhibitory activity similar to lam-D.

The cytotoxicity was improved after glycosylation with glucose or galactose at the C-8- and C-20-OH positions of lam-D.<sup>4</sup> The structure–activity relationships in the lam-D analogs (29, 30) revealed that small changes in their structure are sufficient to reduce, and in some cases to lose, the cytotoxicity of this parent alkaloid. The studies showed that hydroxyl groups at the C-8 and C-20 positions would be essential for their cytotoxicity. In contrast, the methoxy groups at C-13 and C-21 positions appeared to be less important for the cytotoxic activity.<sup>10</sup> Notably, the high activity of alkaloids 1, 9, and 13, which possess two hydroxy groups at C-8 and C-20 positions, supported our previous SAR study described above.<sup>3</sup> However, the increase in the number of methylations and/or

methoxylations in lamellarins appears to cause a decrease in the anti-tumor activities.<sup>15</sup>

In most cases, the cytotoxic activity of lamellarins-type Ia was lower than of lamellarins-type Ib, as exemplified by the lamellarin M (5) ( $IC_{50} = 0.04$   $\mu$ M against A549) *versus* lamellarin K (3) ( $IC_{50} = 4.2$   $\mu$ M against A549) case, as well as the 5,6-double bond compared between lam-D (1) ( $GI_{50MCF-7}/GI_{50HCT-116}/GI_{50NCI-H522} < 0.01$   $\mu$ M) and lamellarin  $\chi$  (14) ( $GI_{50MCF-7} = 0.98$   $\mu$ M;  $GI_{50HCT-116} = 0.78$   $\mu$ M;  $GI_{50NCI-H522} = 0.27$   $\mu$ M).<sup>3</sup> Lamellarins 5, 11, and 12, possessing a C-7 hydroxy group, also showed high activity even when the methyl group blocked the hydroxy group at the C-8 position. These findings suggested that the hydroxy group could be placed at either C-7 or C-8 positions. The pioneer works<sup>8,14,18,19,27–33</sup> have contributed to the discovery and synthesis of new lamellarins and then to the characterization of the modes of action of this group of marine alkaloids. Most of these natural and synthetic lamellarin derivatives have been characterized from a chemical and structural point of




Fig. 2 Some lamellarin compounds as promising inhibitors. (1) Lamellarins with potent anti-topoisomerase activity; (2) some lamellarins as potent protein kinase inhibitors.





view, but until today their mechanisms of action remain incompletely understood.

### Biochemical mechanisms of lamellarins

Our knowledge of the action mode of natural products is fragmentary, which is certainly also the case for lamellarins. Lamellarins are potent cytotoxic agents; however, their antiproliferative activity on cancer cells *in vitro* varies according to the structural characteristics of such alkaloidal molecules (Fig. 2). At the molecular level, the mechanism of action of lamellarins remains largely unknown. The only member extensively studied is lam-D which has been the subject of many pharmacological studies over the past 12 years.<sup>1</sup> In 2003, Bailly and co-workers discovered that the lam-D functions as a poison of the Topo-I enzyme. Still, it is clear now that a pleiotropic mode of action is responsible for its antiproliferative activity in cancer cells.<sup>34</sup> As detailed below, at least three types of effects have been described for this marine alkaloid and its related products.

### Inhibition of topoisomerase I

Topoisomerase I is a nuclear enzyme that facilitates the relaxation of supercoiled DNA for the duration of replication, transcription, and other nuclear processes *via* single-strand DNA cleavage and relegation.<sup>2</sup> Human Topo-I forms a tightly closed clamp around the DNA, and modulation of this mechanism of transcriptional regulation is driven by different proteins, such as the tumor suppressor p53, which alters the enzyme's catalytic activity. This action of the inhibitors causes single-strand DNA cleavage, which is then transformed into double-strand DNA cleavage that is lethal for growing cells. The prototypic inhibitor of human Topo-I is the plant alkaloid camptothecin (CPT) which specifically stabilizes the intermediate covalent complexes between DNA and Topo-I. Specific binding of CPT at the Topo-I–DNA interface stabilizes the phosphotyrosyl linkage; whereby, the enzyme is linked to one strand of the double helix.<sup>18</sup> CPT converted supercoiled plasmid DNA into the nicked DNA form in the presence of human recombinant Topo-I, and a similar effect is observed with lam-D.<sup>8,26</sup> Although the drug concentration required to convert supercoiled DNA into simple form is approximately five times higher than CPT. In contrast to camptothecin, lamellarin D slows down the relaxation of mitochondrial Topo-I and strongly inhibits DNA relegation by this mitochondrial enzyme.<sup>35</sup>

The initial study of Faulkner and coll. on the Topo-I inhibition by a series of ascidian alkaloids, *i.e.*, the lamellarins involved HIV-1 integrase and the topoisomerase of the *Molluscum contagiosum* virus (MCV),<sup>36</sup> indicated that whereas none of the studied compounds as 20-sulfate of lamellarin- $\alpha$ , U, and V (31–33), and non-sulfated forms of lamellarin N (9), T (34), and W (35) (Fig. 2) inhibited MCV topoisomerase at concentration <100  $\mu$ M, only lamellarin- $\alpha$  20-sulfate showed selective inhibitory activity against HIV-1 integrase and HIV-1 virus in cell culture ( $IC_{50}$  = 8  $\mu$ M), being less toxic in HeLa cells ( $LD_{50}$  = 274  $\mu$ M).

In contrast, lamellarin-A does not inhibit HIV-1 integrase but shows moderate cytotoxicity with good cell line selectivity.

Subsequently, it was found that lam-H (16) had a potent anti-topoisomerase activity ( $IC_{50}$  = 0.23  $\mu$ M) but lacked the specificity required to be medicinally useful given that it was quite cytotoxic toward HeLa cells ( $LD_{50}$  = 5.7  $\mu$ M).<sup>37</sup> In addition, lamellarins M (5), N (9), H (16), X (11), W (35), and B (36) (Fig. 1 and 2) also showed potent inhibition of human Topo-I.<sup>2</sup> On the other hand, lam-N analogs were utterly inactive against Topo-I even at 50  $\mu$ M and less potent than lam-D.

However, parental lam-N inhibited the action of Topo-I. This interesting result may be accounted for considering the unfavorable steric interactions between the 16-methyl group of alkaloids 37 or 38 and the base pairs of DNA, preventing the formation of a stable compound–DNA–Topo-I ternary complex.<sup>21</sup> The phenotypic cytotoxic activities of 37 ( $IC_{50}$  2.0–4.1  $\mu$ M) and 38 ( $IC_{50}$  0.16–0.79  $\mu$ M) agree with no inhibition of Topo-I, observing that the lower cytotoxicity of these compounds may be considered by the lack of their Topo-I inhibitory activity.

Lamellarin D (1), a potent inhibitor of human Topo-I, breaks and rejoins DNA strands through a DNA-3'-phosphotyrosyl-enzyme intermediate.<sup>18</sup> Like other topoisomerase inhibitors, it stabilizes the DNA–Topo-I complex. Its main target is nuclear and mitochondrial Topo-I.<sup>32</sup> The C-8–OH and C-20–OH groups of lam-D participate in hydrogen-bonding interactions with the enzyme's side chains of Glu356 and Asn722.<sup>1</sup> Lam-D maintains a significant level of cytotoxicity in the Topo-I-mutated cells (P388CPT5) resistant to the camptothecin, a reference Topo-I poison. These results raise the possibility of “double hits” of lam-D, one directly on the mitochondria to trigger apoptosis and the other located in the cell nucleus, resulting in DNA damage, cell cycle arrest, and DNA repair.<sup>26</sup> In other matters, the relative resistance index (RRI) is significantly reduced with lam-D (RRI = 21) compared to CPT (RRI = 103) against P388CPT5.<sup>8</sup>

Mannich derivatives of lam-D like heterocycle 39 were evaluated for their *in vitro* anti-cancer and Topo-I inhibitory activities at an equivalent level to that of lam-D, reporting that the compound SL-9 (39) showed a better Topo-I inhibitory activity than that of lamellarin D.<sup>38</sup> Likewise, Colligs *et al.* synthesized new lam-D derivative (lamellarin G trimethyl ether) which displayed lower antiproliferative activity than CPT against drug-sensitive human leukemic lymphoblasts (CCRF-CEM cells) but with less resistance effect on multidrug-resistant CEM/ADR5000 cells.<sup>9</sup> Lamellarin D and some related derivatives were effective in stabilizing the DNA–Topo-I covalent complex.<sup>11</sup> Among these derivatives, lam-D and its analog 40 more effectively exhibited the lymphoblastic cells (CEM) and the camptothecin-resistant human T leukemia cells (CEM/C2) presenting the following values for 1  $IC_{50}$  = 5 nM/ $MIC_{50}$  = 720 nM and for 40  $IC_{50}$  = 17 nM/ $MIC_{50}$  = 2740 nM. Molecular docking analysis of 1 into the Topo-I-binding site supported the role of hydrogen bonds between C-8–OH, C-20–OH groups, and carbonyl oxygen at the C-17 position with Asn722, Glu356, and Arg364, respectively. This study suggested that the planar pentacyclic lamellarin moiety, bearing hydroxyl groups at C-8 and C-20, is essential for inhibiting Topo-I. On the other hand, the aryl ring at C-1 (F-ring) is directed toward the major groove cavity and does not directly interact with the enzyme. This model suggests that the F-ring is probably not essential for Topo-I inhibition.<sup>2,11</sup>



A new class of Topo-I inhibitors with the benzo[*g*][1]benzo-pyran[4,3-*b*]indol-6(13*H*)-one scaffold (BBPI) was generated by switching the positions of the pyrrole nitrogen and C-1 of lam-D. The Topo-I inhibitory activities of the selected BBPIs [*N*-methyl (41), *N*-ethyl (42), *N*-(2-dimethylamino)ethyl (43), and valine ester (44)] derivatives (Fig. 2) demonstrated higher activity than CPT and the parental.<sup>2</sup> BBPI derivatives were designed to possess a planar polyaromatic structure similar to the type Ib lamellarin core, which enabled intercalation between the duplex DNA base pairs and the two hydroxy groups at positions corresponding to C-8 and C-20 in lamellarin to form hydrogen bonds with Asn722 and Glu356 of Topo-I.<sup>3</sup> The inhibition of nuclear and mitochondrial Topo-I is not the only mechanism by which lam-D causes the decrease of the cancer cells' growth. Indeed, poisoning of mitochondrial Topo-I triggers oxidative stress and DNA damage.<sup>11</sup> A link has now been established between the molecular action of lam-D on mitochondrial Topo-I and the mitochondrial cascade of events (inhibition of respiratory chain, swelling of the mitochondrial matrix).<sup>1</sup> Due to the latter activity, lamellarin D retains cytotoxicity against CPT-resistant cancer cells.<sup>34</sup>

Structure–activity studies indicate a good correlation between Topo-I inhibition and cytotoxicity of lam-D derivatives, suggesting that one of the proapoptotic targets of lam-D is in the cell nucleus.<sup>26</sup> The observed correlation between cytotoxicity and Topo-I inhibition indicated that Topo-I-mediated DNA cleavage assays could be used to guide the development of anti-cancer agents.

### Inhibition of protein kinases

Apart from human Topo-I, other DNA interacting enzymes may contribute to the mechanism of action of the lamellarins. In 2008, Meijer and co-workers identified a new molecular target of anti-cancer lamellarins. They showed that certain lamellarins could interfere with the activity of a wide range of protein kinases relevant to cancer,<sup>39</sup> including dual specificity tyrosine phosphorylation activated kinase 1A, glycogen synthase kinase-3 (GSK-3), casein kinase 1, PIM-1 and cyclin-dependent kinases (CDKs).<sup>20</sup>

Lamellarin D displays unselective kinase inhibition (CDK1, CK5, GSK3, PIM1, and DYRK1A) in the sub-nanomolar range.<sup>32</sup> A library of substituted chromeno[3,4-*b*]indoles as Lamellarin isosteres was achieved, allowing the identification of two lead compounds as new nanomolar inhibitors of the kinase DYRK1A (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase, that is a potential drug target for neurodegenerative diseases and cancer.<sup>40</sup> It was noted that lam-D was a modest kinase inhibitor, with IC<sub>50</sub> values in the low μM range, whereas lam-N proved to be much more potent with IC<sub>50</sub> values (against glycogen synthase kinase 3, GSK-3) in the nM range.<sup>41</sup> But it also affected many other kinases to a lesser extent.<sup>1</sup> Furthermore, Ruchirawat and co-workers evaluating the GSK-3β inhibitory activity of lam-D, lam-N, and azalamellarins D (45) and N (46), showed that following the order of inhibition: azalamellarin N (IC<sub>50</sub> = 0.008 μM) > azalamellarin D (IC<sub>50</sub> = 0.018 μM) > lam-N (IC<sub>50</sub> = 0.036 μM) > lam-D (IC<sub>50</sub> = 0.32 μM). Therefore, replacing

the lactone moiety of the lam-D ring skeleton with a lactam ring of the azalamellarin structure markedly increased the kinase inhibitory activity.<sup>42</sup>

The kinase inhibition may contribute, at least to some extent, to the cytotoxic and pro-apoptotic properties of lam-N. A series of A-ring-modified lamellarin N analogs were synthesized and evaluated as potential inhibitors of the epidermal growth factor receptor, EGFR T790M/L858R, a causal factor in drug-resistant non-small cell lung cancer. It was found that lam-N alkaloid and the most promising analog 47 displayed an excellent inhibitory profile against the T790M/L858R mutant (IC<sub>50</sub> = 31.8 nM).<sup>43</sup> In addition, the kinase inhibitory activities of the lam-N synthetic analogs were also evaluated on eight protein kinases relevant to cancer and neurodegenerative diseases (CDK1/cyclin B, CDK2/cyclin A, CDK5/p25, GSK-3α/β, PIM1, DYRK1A, CLK3, and CK1). Whereas isomer (aR) (38) exhibited potent but nonselective inhibition on all protein kinases except CK1 (IC<sub>50</sub> = 0.024–0.21 μM), its isomer (aS) (37) selectively inhibited only GSK-3α/β, PIM1, and DYRK1A (IC<sub>50</sub> = 0.22–0.44 μM). A good correlation was observed between the effects of lamellarins on protein kinases and their action on cell death, suggesting that inhibition of specific kinases may contribute to their potent cytotoxicity.<sup>21</sup> Synthetic analogs showed inhibitory effects toward protein kinases but were inactive toward the Topo-I enzyme. This is attributed to the unfavorable steric interaction of the methyl group and the DNA base pairs.<sup>11</sup> Notably, lam-N showed selectivity for a few kinases on a Cerep kinase panel, some of which were identified as major cancer targets, such as VEGFR1/2, Flt-3, PDGFR, LcK, and Lyn.<sup>3</sup>

The above-discussed results suggested that protein kinases that transfer a phosphate group to a protein while phosphatases remove a phosphate group from protein may contribute to the drug's cytotoxicity. Consequently, the structural requirements for protein kinase inhibition are as follows: (1) the hydroxy groups at C-8 and C-13 are essential for inhibition, whereas the hydroxy groups at C-14 and C-20 are less critical; (2) the C5=C6-double bond, *i.e.*, the planar structure of the pentacyclic core, is essential for a high activity. These requirements are somewhat different from those required for the Topo-I inhibition and cytotoxic activity that suggests the possibility of producing selective kinase inhibitors according to the needs at the molecular level.<sup>3</sup>

### Inhibition of mitochondrial function

In recent years, mitochondria have emerged as a promising target for cancer therapy.<sup>26</sup> Mitochondria play a crucial role in the apoptotic process induced by chemotherapeutic agents.<sup>44</sup> These organelles can represent an attractive primary anti-cancer drug target. They may act on different mitochondrial locations, including the Bcl-2 protein family, the respiratory chain complexes, and the mitochondrial permeability transition (MPT) pore constituents, representing attractive pro-apoptotic targets for new anti-cancer drugs.<sup>45</sup>

Lamellarin D (1) acts on cancer cell mitochondria to induce apoptosis through early disruption of the inner mitochondrial transmembrane potential (Δψ<sub>m</sub>) in the P388 leukemia cell line.



The direct mitochondrial effect of lam-D accounts for the sensitivity of Topo-I-mutated P388CPT5 cells resistant to CPT. Interestingly, the effects of **1** on  $\Delta\psi_m$  occurred over the same concentration range ( $5 \mu\text{M L}^{-1}$ ), suggesting that the proapoptotic effect of lam-D depends on the functional alterations of mitochondria.<sup>8</sup> Furthermore, lam-D alone cannot promote apoptosis of the isolated core. These data suggested that lam-D induces apoptosis of Topo-I-mutated cells *via* its effect on MPT, a process used by mitochondria to activate cell death.<sup>26</sup> In 2009, Bailly *et al.*, reported extensive studies using various tumor cell lines; their results indicated that lam-D exerts its cytotoxicity for all cell types tested primarily by inducing mitochondrial apoptosis independently of nuclear signaling.<sup>26</sup>

Interestingly, a tumor-active lam-D analog, titled PM031379 (**27**) exerted a direct proapoptotic action on mitochondria *via* the generation of reactive oxygen species and up-regulation of the apoptosis-inducing factor, which have been seen in the non-small cell lung cancer cell line, U1810.<sup>1</sup> The amino derivative PM031379 did not stabilize Topo-I-DNA covalent complexes. However, this derivative produced a dose-dependent increase in tumor cell death through a mitochondrial-dependent pathway. These effects are equally potent and rapid with lam-D analog compared with its parental, suggesting that mitochondria are the target of both compounds.<sup>8</sup> Other studies examined the apoptosis induction of lam-D and related synthetic products (compound analogs lacking the 20-OH or 8-OH group) at  $5 \mu\text{M}$  in Jurkat leukemia cells.<sup>45</sup> These derivatives induced nuclear apoptosis by acting directly on mitochondria. However, its analogs with various substitutions at positions C-8, C-14, and C-20 failed to induce mitochondrial apoptosis. The analysis of the structure–apoptosis relationships points to a critical role of the OH groups at positions C-8 and C-20 for this effect. These results were consistent with previous reports demonstrating that hydroxyl groups are essential structural requirements for cytotoxic activity. Thus, lam-D and analogs appear to have unique mitochondrial mechanisms of action, leading to cancer cell death.

### Synthetic strategies in the total synthesis of lamellarins

Lamellarins and related pyrrole-derived alkaloids have attracted great interest as targets for total synthesis. Several research groups have reported the synthesis of lamellarins and related


pyrrole-derived alkaloids, including extended/condensed structures. Consequently, extensive efforts have been devoted to creating novel structures and improving synthetic methods, leading to these natural marine alkaloids.<sup>1</sup>

Several elegant synthetic strategies have been employed in which highly functionalized precursors were assembled into the pyrrole core through intramolecular ylide cycloaddition,<sup>46</sup> azadiene Diels–Alder cycloaddition,<sup>47</sup> oxidative dimerization,<sup>28</sup> among others. Owing to their interesting structural features and promising biological activities, many synthetic chemistry groups have developed efficient strategies for the total synthesis of lamellarins and related analogs.

In 1997, Ishibashi's group achieved the first total synthesis of these marine alkaloids, *i.e.*, lam-D and lam-H by *N*-ylide-mediated cyclization using benzyloquinoline derivative as the critical ring construction procedure in five steps; yields of lam-D (**1**) and lam-H (**16**) were 18% and 15%, respectively<sup>46</sup> (Scheme 1). The synthesis of 1-dearyllamellarin D was reported in 2006.<sup>33</sup> The main precursor, *N*-alkaryl pyrrollo-coumarin derivative **63** was obtained by the use of the Mitsunobu reaction of the lactone **54** with alcohol **55** in the presence of diisopropyl azodicarboxylate (DIAD) and triphenylphosphine. Its palladium-catalyzed intramolecular direct arylation afforded pentacyclic derivative **64** in 89% yield which then, was converted into **65** *via* the dehydrogenation reaction under mild conditions ( $\text{MnO}_2/\text{CH}_2\text{Cl}_2$ , reflux) in good yield. Synthesis of 1-dearyllamellarin D (**66**) ended with a simple procedure, selective deprotection of the isopropyl groups ( $\text{BCl}_3$ ) (Scheme 2).


The total synthesis of lamellarin R (**67**), belonging to non-fused 3,4-diarylpyrrole marine alkaloids was performed by Jia and co-workers.<sup>48</sup> The lineal synthesis in 5 steps started with an aldehyde **68** and *p*-methoxyaniline **69**; their oxidative coupling reaction smoothly afforded a pyrrole derivative **70** and, consequently, its traditional Vilsmeier–Haack reaction ( $\text{POCl}_3/\text{DMF}$ ) produced pyrrole-aldehyde **71**. The Lindgren oxidation of **71** under the optimized conditions allowed to prepare pyrrole-acid **72** whose treatment with  $\text{TMSCHN}_2$  gave methyl ester **73**, and finally, the demethylation reaction of **73** provided marine alkaloid of Type-II, lamellarin R (**67**) (Scheme 3).

On the other hand, the total synthesis of lam-D, lam-H, and lam-D trimethyl ether has also been accomplished using  $\text{Ru}(\text{II})$ -catalyzed  $[3 + 2]$  annulation strategy to construct the central




Scheme 1 Synthesis of lamellarins D (**1**) and H (**16**).






Scheme 2 Synthesis of 1-dearyllamellarin D (66).



Scheme 3 Total synthesis of lamellarin R (67).



Scheme 4 Total synthesis of lam-D (1), lam-H (16), and lam-D trimethyl ether (82), through various Ru(II)-catalyzed C-H activations.






pyrrole ring.<sup>49</sup> The striking features of this synthesis were the use of PEG-400 as a green solvent for various Ru(II)-catalyzed C–H activations. The synthetic sequence begins with the annulation reaction of enamide **74** and diarylalkyne **78a** to give 2,3-diarylpyrrole-5-carboxylate **75a**. Its bromination reaction easily provided bromide derivative **77a**, a suitable precursor for the Suzuki reaction with boronic acid **76a**. Thus, triaryl-substituted pyrrole **79a** was obtained using catalytic Pd(dba)<sub>2</sub>/1,1'-bis(diphenylphosphino)ferrocene (dppf) system in DME-H<sub>2</sub>O medium (Scheme 4).

Then, one-step lactonization process by methoxymethyl ether (MOM)-deprotection catalyzed by *p*-TsOH in MeOH afforded the lactone ring of **80a**. Its *N*-alkylation with

bromoacetaldehyde diethyl acetal allowed to prepare **81a** and its cyclization under mild reaction conditions (TfOH/CH<sub>2</sub>Cl<sub>2</sub>, 0 °C) gave lam-D trimethyl ether (**82**) in 94% yield.

The global deprotection of the methyl groups with BBr<sub>3</sub> yielded lam-H (**16**) in 83% yield. Finally, using the lam-D trimethyl ether (**82**) obtained, lam-D was easily prepared in 79% yield after the treatment with BCl<sub>3</sub> (Scheme 4). Colligs and coworkers also reported the synthesis of marine alkaloid **82** based on von Miller–Plöchl cyclocondensation of a deprotonated  $\alpha$ -amino nitrile with an  $\alpha,\beta$ -unsaturated ketone as a critical step, where this alkaloid was accessed by two different synthetic routes (Scheme 5, route 1).<sup>50</sup>



**Scheme 5** General presentation of synthetic approaches for lam-G trimethyl ether (**83**) and its derivatives **100a–100d**. Route 1: synthesis of lam-G trimethyl ether (**83**) by von Miller–Plöchl-Type cyclocondensation based on two different synthetic routes; Route 2: synthesis of dihydro-lamellarin  $\eta$  (**100b**) and lamellarin  $\eta$  (**100d**) from an intermediate of lam-G trimethyl ether **100a**.



In general, block A (arylboronic acid **87**) was built in three steps from 3,4-di-methoxy phenol **84**. Blocks D and E ( $\alpha$ -amino nitrile **88**) were made from homoveratrylamine **89**, which was converted into dihydroisoquinoline **90** through the subsequent Bischler–Napieralski-reaction. Blocks F and C (dimethoxybutan-2-one derivative **91**) were built by aldol condensation of veratraldehyde **92** with 1,1-dimethoxypropan-2-one.


Thus, the modified von Miller–Plöchl reaction of the deprotonated  $\alpha$ -amino nitrile **88** and enone **91** afforded aryl-pyrrolo[2,1-*a*]isoquinoline F-EDC skeleton **93**. To introduce the aryl substituent in a 2-position (ring A), the bromination reaction with NBS was carried out affording **94**. In the first route, diaryl-pyrrolo[2,1-*a*]isoquinoline **95** was formed for coupling the brominated dihydroisoquinoline **94** and boronic acid **87**. Eventually, the cyclization's hemiacetal product **96** must be oxidized to give the desired lamellarin **83**. In the second route, the acid **97** was obtained *via* the Pinnick oxidation to form the soluble ester **98** leading to the synthesis of desired lamellarin **83** in a few steps. Indeed, this route was more efficient than the first route. Imbri *et al.* reported the synthesis of dihydro-lamellarin  $\eta$  (**100b**) and lamellarin  $\eta$  (**100d**) from an intermediate of lam-G trimethyl ether **100a**<sup>51</sup> (Scheme 5, route 2).

To get lamellarin  $\eta$  (**100d**) from alkaloid **100a**, the generation of the 5,6-double bond was necessary that was achieved using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to furnish intermediate **100c**. Its post-debenzylation with  $\text{BCl}_3$  gave marine alkaloid **100d**. Concurrently, dihydro-lamellarin  $\eta$  (**100b**) was

obtained from **100a** under the same debenzylolation reaction conditions. Recently, the first late-stage pyrrole C–H arylation in a lamellarin alkaloid synthesis to obtain lam-D (**1**) using *ortho*-ester-masked  $\alpha$  was reported; traditional routes to lamellarins have almost universally used pyrrole halogenation followed by C–C cross-coupling reactions<sup>52</sup> (Scheme 6). Lam-D was obtained from 1,4-dicarbonyl derivative **102** previously synthesized (not described below). The lam-D synthesis starts with the cyclocondensation of **102** and **103**.

Thus, treating **102** with aminoacetaldehyde diethyl acetal **103**, led to the formation of the desired pyrroloisoquinoline product **104**. Its subsequent treatment with Pd-catalyst on carbon in a MeOH/AcOEt mixture gave a pentacyclic alkaloidal system **105**. Notably, this reaction allowed the construction of the fused coumarin ring in a single step. The key C–H arylation of **105** with aryl halide fragment **106** was accomplished by utilizing nucleophilic aromatic substitution of 5-bromo-2-fluoroanisole **107** at C-2 with iso-PrOK, and eventually, all *O*-isopropyl protected lam-D **108** was isolated. Finally, the synthesis accessed the lam-D alkaloid using  $\text{BCl}_3$  to remove all isopropyl groups.

The pentacyclic skeleton diversification has provided an attractive template to incorporate other functional or protective groups. Moreover, the hydroxyl groups around the lamellarin core can be easily substituted with labile moieties to build prodrugs.<sup>18</sup> The variation of the substituents on this pentacyclic core and saturated or unsaturated D-ring has allowed for obtaining a large panoply of natural and unnatural derivatives.<sup>1</sup>




**Scheme 6** Synthesis of lamellarin D (**1**). Reagents and conditions: (i) iso-PrOH, *t*-BuOK, PhMe, DMPU, 80 °C, 3 h, 82%; (ii)  $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ , AcOK, DMA, 150 °C, 22 h, 80%; (iii)  $\text{BCl}_3$ , DCM,  $-78$  °C to r.t., 3.5 h, 99%.


Due to the fascinating novel structures and biological activities, more and more researchers have devoted themselves to the synthetic studies of lamellarins and related pyrrolo[2,1-*a*]isoquinoline analogs.

## Approach to the synthesis and diversification of isoquinoline and pyrrolo[2,1-*a*] isoquinoline core

Pyrrolo[2,1-*a*]isoquinoline is a fusion of two privileged frameworks. Furthermore, it is a crucial molecule present in a large number of natural products and synthetic molecules. Notably, most lamellar alkaloids isolated from marine organisms possess the pyrrolo[2,1-*a*]isoquinoline scaffold as their structure. As a result, significant efforts have been made to develop target-oriented and diversity-oriented synthesis strategies for constructing pyrrolo[2,1-*a*]isoquinoline derivatives. The evolution of new catalysts, reaction conditions, and reagents has increased the ability to create efficient, regioselective, stereo-specific, and robust methods.<sup>53–55</sup> Recent advances in the methodologies employed in the synthesis of isoquinolines as precursors and pyrrolo[2,1-*a*]isoquinolines are presented.



Scheme 7 Classical strategies for the isoquinoline synthesis.




Scheme 8 Emerging synthetic approach for isoquinoline synthesis.

### Strategies in the construction of isoquinolines

The construction of the isoquinoline core uses classic synthetic strategies such as the Pomeranz–Fritsch synthesis, which shows the acid-promoted synthesis of isoquinoline **109** from benzaldehyde **110** and a 2,2-dialkoxyethylamine **111** in two steps.

Condensation of aryl aldehyde with amino acetal to form an aryl-alimine and then cyclization of aldimine, or the Pictet–



Scheme 9 Intramolecular cyclization reactions and C–C bond formation on isoquinoline synthesis.



Spengler synthesis which uses  $\beta$ -arylethylamines **112** and carbonyl compounds **113** followed by cyclization reaction in strong acids media (hydrochloric acid, trifluoroacetic acid),<sup>56</sup> the Bischler–Napieralski reaction employs  $\beta$ -arylethylamines **115** in phosphorus oxychloride to obtain dihydroisoquinolines **116**,<sup>57</sup> whereas the Pictet–Gams synthesis uses acetoamino-methyl phenylcarbinols **117** phosphorus pentoxide as a reagent to obtain isoquinolines<sup>58</sup> (Scheme 7).

New routes to access the isoquinoline core are still highly desirable, particularly ones with the ability to directly access the isoquinoline moiety in a range of oxidation levels that do not require highly-specialized starting materials (Scheme 8).


These synthetic strategies are based on the type of substrates used, which has a marked influence on the reactivity and conditions; route A involves the use of phenylethylamines **112** and aldehydes (or acid derivatives) **118** as the initial substrate leading to the interaction with electrophilic agents **118** and subsequent cyclization reactions, whereas route B employs synthetic strategies based on the coupling annulation of aromatic aldehydes **110** and amine derivatives **119**.

Route A (see, Scheme 8). The aryl-methylamines combined with diverse electrophilic agents can undergo intramolecular cyclization reactions, including C–C bond formation. New 1,4-

disubstituted-3,4-dihydroisoquinoline derivatives **123** were synthesized using the amidation reaction of substituted 2-arylethylamines **120** and benzoic acids derivatives **121a** to give substituted benzamides **122** and their subsequent Bischler–Napieralski cyclization which afforded the desired isoquinoline products **123** in good yields (Scheme 9).<sup>59</sup>

A similar synthetic sequence involving Pictet–Spengler cyclization but under microwave irradiation conditions (MW, 140 °C, 30 min) was reported by Awuah and Capretta. Diversely substituted 1-arylisoquinolines **126** were quickly prepared using the cyclization reaction of substituted 2-arylethylamines **124** and benzaldehydes **121b** and subsequent oxidation of intermediate tetrahydroisoquinolines **125** which were converted into the isoquinoline analogs.<sup>60</sup> An approach that provided direct access to multi-substituted isoquinoline **129** is based on the catalytic tandem C–H metalation  $[(\text{Cp}^*\text{RhCl}_2)_2]$  and cyclization–condensation processes ( $\text{AgSbF}_6$ ) of ketoximes based on acetophenones **127** and diazo compounds **128** under mild conditions<sup>61,62</sup> (Scheme 9).

Route B (see, Scheme 8). The strategy usually employs a Brønsted and Lewis acid-catalyzed tandem reactions that simultaneously involve a Michael addition reaction of diverse *N*-nucleophiles to electrophiles (aryl-alkyne(alkene) compounds)



Scheme 10 Brønsted and Lewis acid-catalyzed/Michael addition on isoquinoline synthesis.



with a subsequent cyclization process (annulation, cyclization, or electrophilic substitution) to obtain the isoquinoline core (Xing *et al.* 2016).<sup>63</sup> For example, gold, a soft Lewis acid, mediated domino reaction of readily available 2-alkynylbenzamides **132** and ammonium acetate **133** as a source of  $\text{NH}_3$  molecules to afford substituted 1-aminoisoquinolines **134** in good to excellent yields (Long *et al.* 2013) (Scheme 10).<sup>64</sup> In this reaction, a catalytic  $\text{NaAuCl}_4 \cdot 2\text{H}_2\text{O} - \text{AgSbF}_6$  system worked well under mild reaction conditions and are compatible with various functional groups.

Arambasi and co-workers also reported a one-pot route to isoquinoline compounds **137** which is based on the Rh-catalyzed alkyne carbathiolation reaction of alkynes **136** and acetophenone-containing methyl sulfide group **135** which is achieved by simply adding  $\text{NH}_4\text{OAc}$  and acetic acid directly to the reaction upon completion.<sup>65</sup> The developed method involves the use of the commercially available precursor  $[\text{Rh}(\text{nbd})_2]\text{BF}_4$  and Xantphos phosphine ligand to form *in situ*  $[\text{Rh}(\text{Xantphos})(\text{nbd})][\text{BF}_4]$  complex which presented remarkable activity with full conversion to the isoquinoline product achieved in less than 2 h (Scheme 10). Noteworthy that this one-pot, regioselective synthesis of isoquinolines was due to the presence of the activating 2-SMe groups of acetophenone derivatives.

There are different catalytic systems proposed for isoquinoline synthesis. As an example,  $[\text{Cp}^*\text{RhCl}_2]_2/\text{KOAc}$  catalytic system was developed for the synthesis of polysubstituted isoquinolines **141** using three-component condensation reaction of acetophenones **138**, hydroxylamine **139**, and internal alkynes **140** in a one-pot manner (Scheme 10).<sup>66</sup> The condensation process starts the formation of aryl-ketone oximes under mild conditions, then  $[\text{Cp}^*\text{RhCl}_2]_2/\text{KOAc}$  system generates the active  $\text{Cp}^*\text{Rh}(\text{OAc})_n$  species triggering *ortho*-C-H bond of intermediate acetophenone-oximes and their intermolecular cyclization with alkynes proceeds to give diverse isoquinolines. A highly efficient procedure based on silver triflate catalysis was also proposed for the isoquinoline preparation (Scheme 10).

It involves the cascade addition/6-exo cyclization reaction of 2-alkynylbenzaldehydes **141** and 2-isocyanoacetates **143** in the presence of  $\text{AgOTf}$  and DBU in MeCN at 80 °C for 5 h which allowed to provide isoquinolines **144**. It was believed that isocyanoacetates **142** could attack 2-alkynylbenzaldehydes **141** first in the presence of a base (DBU) to generate an intermediate, a product of the nucleophilic addition to the CHO group, and then it could be transformed into desired isoquinoline products *via* subsequent 6-exo cyclization with a loss of carbon monoxide.<sup>66</sup> Recently, Sestelo and co-workers reported the cycloisomerization reaction of imines derived from *o*-(alkynyl) benzaldehydes using  $\text{InI}_3$  (5 mol%) and the Hantzsch ester (120 mol%), under milder reaction conditions, can conduce to the formation of diverse functionalized 1,2-dihydroisoquinolines through a domino cycloisomerization/reduction approach.<sup>67</sup>

The essential biological properties and the difficulty in obtaining large quantities from the natural sources of lamellarins and related pyrrole-derived alkaloids have attracted great interest as challenging natural product targets for total synthesis.

Mohan *et al.*, 2021: Crispine A type pyrrolo[2,1-*a*]isoquinolines





Fig. 3 General synthetic pathways for constructing pyrrolo[2,1-*a*]isoquinolines.

### Strategies in the construction of pyrrolo[2,1-*a*]isoquinolines

Several synthetic strategies for constructing pyrrolo[2,1-*a*]isoquinolines have been developed. These strategies are classified by pyrrole ring and isoquinoline-based formation (Fig. 3). Recently, various groups performed a detailed and rigorous analysis of these methodologies covering 2010 to 2021,<sup>11,68,69</sup> which revealed the great interest of modern organic chemists in pursuing efficient synthetic routes for the development of lamellarin-derived bioactive compounds.

Developing the pyrroloisoquinoline chemistry, an important modification of pyrrolo[2,1-*a*]isoquinolines **145** with arylacyl bromides **146** in the presence of DMSO as oxidant was made *via* the dicarbonylation reaction which allowed the preparation of 1,2-dicarbonylated pyrroloisoquinolines **145** in acceptable to good yields (12–73%).<sup>70</sup> (Scheme 11). On the other hand, tetrahydroisoquinoline ring is a suitable precursor in the pyrroloisoquinoline chemistry. Thereby, a metal-free approach based on the  $\text{I}_2/\text{DMSO}$  system and a Brønsted acid as catalyst was recently employed for the synthesis of chromone-fused pyrrolo[2,1-*a*]isoquinolines **150** using *o*-acetyl-phenoxy acrylates **148**, tetrahydroisoquinolines **149**, and with iodine in heated DMSO in the presence of TFA for 12 h. This iodine-promoted one-pot cascade oxidative annulation process consists of diverse sequential reactions, *i.e.*,  $\alpha$ -halogenation, oxidation, nucleophilic addition, 1,3-dipolar cycloaddition.<sup>71</sup> Likewise, recently, Cui and Chen used simple tetrahydroisoquinoline, terminal alkyne, and aldehyde precursors for the synthesis of pyrrolo[2,1-*a*]isoquinolines based on a copper-catalyzed three component reaction (A3 type) in the presence of  $\text{CuCl}_2/\text{PhCOOH}$  in DMF at 130 °C. The developed procedure permitted generating various pyrroloisoquinoline derivatives with 17–69% yield.<sup>68</sup> 1-Aroyl-3,4-dihydro isoquinolines **151** were also utilized as simple starting materials in the synthesis of functionalized 5,6-dihydropyrrolo[2,1-*a*]isoquinolines **153** with diverse electron-withdrawing substituents (EWG) at the C-2 position. Reported a convenient procedure involves the treatment of **151** with  $\alpha,\beta$ -unsaturated compounds **152** through the microwave-assisted two-component domino reaction in TFE under reflux.<sup>72</sup>





Scheme 11 Current strategies on pyrrolo[2,1-a]isoquinolines synthesis.

Feng and co-workers also reported a three-component [3 + 2] cycloaddition of 3,4-dihydroisoquinolines **154**, bromoacetates **155** and  $\alpha,\beta$ -unsaturated pyrazole amide **156** in the presence of a chiral  $N,N'$ -dioxide- $Y(OTf)_3$  complex as the catalyst which allowed the preparation of hexahydropyrrolo-isoquinolines **157** in moderate to good yields with excellent diastereo- and enantioselectivities.<sup>73</sup> Similar tetrahydropyrrolo[2,1-*a*] isoquinolin-3(2*H*)-ones **159** were obtained using a tandem Michael addition/carbo-cyclization of 3,4-dimethoxyphenethyl maleimides **158** with carbon, amine, and sulfur nucleophiles (Nu) in the presence of  $\gamma$ - $Al_2O_3$ /TfOH binary system (0.1/1 ratio) at  $-30^\circ C$  followed by reduction using  $NaBH_4$ /MeOH (Scheme 11). It was found that the active species involved in the binary system were  $Al(O)-OH$  which facilitated the Michael addition of nucleophiles such as amines and thiols to maleimides.<sup>74</sup>


Although the use of catalysts is feasible, the vision of the organic chemist is focused on generating methodologies without metals and oxidizing agents. It was also found that the domino reaction of isoquinolinium ylides **160** and electrophilic indoles **161** with KOH in dry DMF at room temperature gave smoothly functionalized pyrrolo[2,1-*a*]isoquinolines **162** in good yields.<sup>75</sup> Zhen and coll use diethyl azodicarboxylate (DEAD) as a dual-functional reagent with both oxidation and dehydrogenation functions. developed a novel metal-free methodology that describes a reliable pathway for synthesizing a range of 5,6-dihydropyrrolo[2,1-*a*]isoquinolines **165** through [3 + 2] cycloaddition/aromatization tandem reactions of alkyl (*e.g.*, benzyl, methyl, ethyl, and *tert*-butyl) 2-(3,4-dihydroisoquinolin-2-(1*H*)-yl) acetates **163** and dimethyl but-2-ynedioate **164** in the presence of DEAD (1.2 equiv.) as the oxidant in dichloroethane (DCE) at room temperature for 12 h.

An iodine- $H_2O_2$  catalytic system in MeCN under reflux conditions also stimulated the preparation of such pyrrolo[2,1-*a*]isoquinolines.<sup>6</sup> Such green-like reaction conditions allowed to prepare easily pyrroloisoquinoline products in good yields.<sup>76</sup> Early, it was developed the first visible-light-driven dipolar [3 + 2] cycloadditions report for the synthesis of pyrrolo[2,1-*a*]isoquinoline *via*  $[Ru(bpy)_3]Cl_2$  as photosensitizer (Zou *et al.* 2011).<sup>77</sup> After ten years, Koohgard and Hosseini-Sarvari employed chlorophyll-a, a natural pigment in the synthesis of pyrrolo[2,1-*a*]isoquinolines **165**<sup>77</sup> (Scheme 11).

Their procedure involves chlorophyll-a-catalyzed dipolar [3 + 2] cycloaddition reaction of **163** as dipoles and **164** as a dipolarophile (among other dipolarophiles 1,4-anthraquinone, acrylonitrile, nitroolefin, activated alkynes, and *N*-arylmaleimides were successfully employed) which carried out in toluene under irradiation conditions with 15 W white LED for 30 h at rt. Although this photocatalytic approach cannot be considered a green strategy because toluene was used as a solvent. However, it is an excellent starting point for further research.

Indolizidine alkaloids, related to the pyrroloisoquinolines are also structurally significant molecules that belong to the broader class of natural products and so, their synthesis has been extensively studied. Recently, it was reported the direct condensation-cyclization reaction of diverse primary amines **166** and dicarboxylic acids **167** for the construction of various indolizidine compounds like **168** and **169**.<sup>78</sup> The condensation was carried out in the presence of an 8.3 wt% mixture of phosphorus pentoxide ( $P_4O_{10}$ ) and TfOH at  $100^\circ C$  followed by reduction (sodium borohydride) of the subsequent iminium ion to produce the final products **168** and **169** (Scheme 12). The use of diverse aliphatic and aromatic dicarboxylic acids with various





Scheme 12 Synthesis of pyrrolo[2,1-a]isoquinoline pseudo-natural products.

primary amines makes this method suitable also for synthesizing pyrrolo-, pyrido-, and isoindolo[2,1-a]isoquinolines in excellent yields.

Due to the continuous interest in pseudo-natural products, modifications of known molecular scaffolds are one of the important directions employed in organic and medicinal chemistry. Recently, a microwave-assisted three-component domino metal-oxidizing agent-free reaction of 1-aryl-3,4-dihydroisoquinolines **151**, terminal alkynes **170**, and cyclic NH-acids **171** (cyclic NH-amides and NH-azoles) in dry acetonitrile at 130 °C makes it possible to obtain quickly C-3-*N*-functionalized pyrrolo[2,1-a]isoquinoline derivatives **172**.<sup>79</sup> On the other hand, metal-catalyzed reactions for preparing new functionalized pyrrolo[2,1-a]isoquinolines are still relevant because it makes easy the diversification of pyrroloisoquinoline skeleton.

Thus, Cui's Group found that an iron catalysis ( $\text{FeCl}_3$ ) in air as the terminal oxidant allowed the synthesis of 5,6-dihydropyrrolo[2,1-a]isoquinoline derivatives **176** using three-component condensation reaction of easily available tetrahydroquinolines **173**, arylacyl bromides **174**, and nitroolefins **175** in chlorobenzene at 120 °C.<sup>68</sup> The formation of final products carried out through the consecutive *N*-alkylation/oxidative 1,3-dipolar cycloaddition/elimination/aromatization process. Analogous trifluoromethylated 5,6-dihydro-pyrrolo[2,1-a]isoquinolines **179**, which are problematic to get ready *via* traditional methods, were promptly obtained in one-pot manner through a tungsten-catalyzed decarboxylative [3 + 2] cycloaddition aromatization process, in which *N*-substituted tetrahydroquinolines **177** reacted with the commercially accessible 2-(trifluoromethyl)acrylic acid **178** in the presence of W-complex  $\text{WO}_2\text{PC}$  in DMF under visible light irradiation using 450 nm LEDs (3W × 4) under oxygen atmosphere for 4 h.<sup>80</sup> This photocatalytic reaction was found tolerant to multiple functional groups, including ester, nitrile, ketone, and alkenes.

Noteworthy that the trifluoromethyl moiety exhibited unique properties such as enhanced lipophilicity, metabolic stability, and the ability for non-covalent interactions with biological targets that could be pharmaceutically useful for the trifluoromethyl substituted lamellarins research. Spiroheterocyclane- and dispiroheterocyclane- [2,1-a]isoquinolines are also complex structures related to lamellarin alkaloids and of great importance for the development of medicinally active drugs.<sup>81,82</sup> Accordingly, the highly diastereoselective construction of the pyrrolo[2,1-a]isoquinoline scaffold and its modifications with spiro-oxindole cores **182** and **184** are attractive due to their versatile biological properties. Although their structures look very complex, efficient three-component approaches for the stereoselective preparation of these spiro-heterocycles do not need a metal catalyst or additive.<sup>83–85</sup> They are based on the 1,3-dipolar cycloadditions of tetrahydroisoquinolinium ylides, appropriately produced *in situ* from hydrogenated isoquinolines **173** and isatins **180**, and the third component such as chalcones **181** or thiazolo[3,2-a]indole derivatives **183** (Scheme 12). Excellent yields with high regio- and stereoselectivity added to the easy purification of these spiro heterocyclic products make an attractive and valuable method for synthesizing complex pseudo-natural spiro-heterocycles based on pyrrolo [2,1-a]isoquinoline core.


In a brief manner, it can be concluded that current research remains on the synthesis of the pyrrolo[2,1-a]isoquinoline moiety and its modifications toward diversity-oriented organic synthesis. Therefore, finding suitable reaction conditions is a never-ending task.

### Structure–activity relationships of pyrrolo[2,1-a]isoquinolines compounds

Like lamellarin alkaloids, some synthetic pyrrolo[2,1-a]isoquinolines (**186–188**) possess cytotoxic properties (Scheme 13)



## Pyrrole ring modifications



## Schiff base modifications

## Pyrrole ring modifications based on tamoxifen structure

Scheme 13 Pyrrolo[2,1-a]isoquinoline analogs as anti-cancer agents, structure-activity relationship analysis.

and act as Topoisomerase inhibitors. The pyrrolo[2,1-*a*]isoquinolines **185a–e** were synthesized and tested against MCF-7 (human breast cancer), Hep-G2 (human liver carcinoma), A549 (human lung cancer), T47D (human breast cancer), and HeLa (human cervical cancer) cell lines, showing weak to moderate cytotoxic activity towards A549 and HeLa.<sup>86,87</sup> Also, it was found that the cytotoxic activity of 2-phenyl-5,6-dihydropyrrolo[2,1-*a*]isoquinolines **185a–d** was very similar to that of 5,6-dihydropyrrolo[2,1-*a*]isoquinoline-1-carboxylates **186a–e**, suggesting that the phenyl ring at the C-1 position is not essential for the activity. Noteworthy that 2-(*p*-methoxyphenyl) pyrroloisoquinoline **186b** displayed a good activity against MCF-7 (IC<sub>50</sub> = 9.4 μM) and Hep-G2 (IC<sub>50</sub> = 4.2 μM) cell lines, whereas its analogs **186c**, **186d** were less active. Docking calculations revealed a good overlap of **186b** with topotecan at the Topo-I binding site. This study emphasizes the importance of the

electronic effects of *meta*-methoxy substituent in the C-2-phenyl group. The role of these organic frameworks on the cytotoxic effects were also evaluated on six tumor cell lines, PC-3 (human prostatic adenocarcinoma), U-251 (human glioblastoma), K-562 (human chronic myelogenous leukemia), HCT-15 (human colorectal adenocarcinoma), MCF-7 (human mammary adenocarcinoma) and SKLU-1 (human lung adenocarcinoma).<sup>86,87</sup> Analyzing the results obtained, it was noted that the C-2 phenyl substituted **186b** showed an increase of cytotoxic activity in U-251 (IC<sub>50</sub> = 4.86 μM), HCT-15 (IC<sub>50</sub> = 0.14 μM), SKLU-1 (IC<sub>50</sub> = 0.59 μM), PC-3 (IC<sub>50</sub> = 18.15 μM) and MCF-7 (IC<sub>50</sub> = 25.2 μM) cell lines. Interestingly, replacement of phenyl ring (**186a**) by the thiophene ring (**186c**) increased the activity against PC-3 prostate cells (IC<sub>50</sub> = 8.47 μM) compared with another series of pyrroloisoquinoline carboxylates **187a–d**.



On other hand, in this series, *meta*-aminophenyl ring **187a** improved the inhibitory activity in U-251 ( $IC_{50} = 5.96 \mu M$ ), K-562 ( $IC_{50} = 2.5 \mu M$ ), MCF-7 ( $IC_{50} = 1.3 \mu M$ ), and SKLU-1 ( $IC_{50} = 0.10 \mu M$ ) cell lines compared with its analogs **187b–d**. Thus, these results could suggest also the importance of the 2-phenyl ring-bearing *meta*-electron-donating groups group such as  $-NH_2$  or  $-OH$  (**187a** and **187b**), *i.e.*, modifying the electronic properties and aromaticity of the C-2 substituent could considerably influence on the antiproliferative activity. Remarkably, the derivative **187a** was more potent than topotecan or camptothecin drugs in HCT-15 (colon) cell lines ( $IC_{50} = 0.01 \mu M$  *vs.*  $IC_{50} = 0.50 \mu M$  or  $IC_{50} = 0.13 \mu M$ ), while its hydroxy analog **187b** resulted to be more effective than cisplatin drug in PC-3 (prostate) cell lines ( $IC_{50} = 0.76 \mu M$  *vs.*  $IC_{50} = 8.30 \mu M$ ). These results confirmed that the cytotoxic activity depends upon the chemical nature of 2-aryl substituents.<sup>86</sup>

Notable, the synthesized pyrroloisoquinoline with *meta*-(cyclohexylmethylpiperazinamide)phenyl fragment **188** exhibited an inhibitory activity in the nanomolar range in U-251 ( $IC_{50} = 50$  nM), HCT-15 ( $IC_{50} = 20$  nM) and SKLU-1 ( $IC_{50} = 20$  nM) cell lines. Moreover, this derivative displayed inhibitory activity in K-562 ( $IC_{50} = 0.16 \mu M$ ) and SKLU-1 ( $IC_{50} = 20$  nM) cell lines even stronger than camptothecin ( $IC_{50} = 0.59$  and  $0.15 \mu M$ , respectively). This is much better than the above-mentioned series of 5,6-dihydropyrrolo[2,1-*a*]isoquinoline-1-carboxylates **186**, **187**.<sup>87</sup>

Synthetic lamellarin analogs were evaluated for their ability to inhibit P-gp and MRP1 efflux pumps in MDCKMDR1 (overexpressing P-gp protein) and MDCK-MRP1 (overexpressing MRP1 protein) cell lines and screened for their cytotoxic effects in drug combination assays with doxorubicin. In particular, the 3-phenyl-5,6-dihydropyrrolo[2,1-*a*]isoquinoline-2-carbaldehydes **189a**, **189b**, which inhibited P-gp with micromolar potency ( $IC_{50} = 0.24$  and  $0.19 \mu M$ , respectively), reversed *in vitro* MDR of tumor cells to doxorubicin at no cytotoxic concentrations. Regarding the MRP1 inhibitory effect, only C-3-unsubstituted dihydropyrroloisoquinoline-2-carbaldehyde **190** and its Schiff base **191** were slightly more potent than verapamil, which was MRP1-selective positive control. SAR studies emphasized lipophilicity's role in increasing compounds' biological potency.<sup>88</sup> Novel Schiff compounds based on the pyrrolo[2,1-*a*]isoquinoline skeleton **192**, **193** were synthesized and the cytotoxicity was tested against RD (rhabdomyosarcoma), HCT116 (intestinal carcinoma), HeLa (adenocarcinoma of the cervix uterus), and A549 (lung adenocarcinoma) cell lines, some of the synthesized compounds were non-cytotoxic in the low micromolar range ( $<30 \mu M$ ). Moreover, it could be noticed that (i) pyrrolo[2,1-*a*]isoquinoline' Schiff bases were mostly less cytotoxic than the parent aldehydes, (ii) the adducts bearing a phenyl ring at C-3 were generally less cytotoxic than the corresponding unsubstituted compounds, and (iii) homobivalent Schiff base derivatives were significantly less cytotoxic than the corresponding mono Schiff bases.<sup>89</sup>

The compounds **200a–d** were designed by combining the structure of lamellarin analogs and pharmacophore tamoxifen **201**, which prevents estradiol binding to estrogen receptor (ER) in breast cancer cells and consequently slows down the

estrogen-induced cell growth. Also, tamoxifen drug and other ER modulators induce apoptosis. The line cells ER $\alpha$ -positive MCF7 and T47D, ER $\alpha$ -negative MDA-MB-231, and two different cancer cell lines, namely A549 (adenocarcinoma human alveolar basal epithelial cells) and HeLa were used in an MTT-based cell viability assay to determine their effects on the viability of breast cancer cells *in vitro*. Derivatives **200a** and **200c** disclosed cytotoxic activity against all cancer cell lines showing the highest potency against T47D cell lines with  $IC_{50}$  values of  $5.18 \mu M$  for **200a** and  $2.34 \mu M$  for **200c**, contrary to the their analogs **200b** and **200d**; both with morpholine moiety groups, were proved cytotoxic only against HeLa and A549 cell lines.<sup>90</sup>

Until now, information about the anti-cancer properties of pyrrolo[2,1-*a*]isoquinolines is still a bit limited. Few studies covered a complete analysis of their cytotoxic properties, and few were known about their absorption, distribution, metabolism, and excretion characteristics as promising agents in the fight against cancer. However, the available knowledge provides an idea of how valuable and diverse these chemical systems are, and they could undoubtedly be the starting point for future research.

## Conclusions

In this comprehensive review, we have analyzed the biology and chemistry of the fused pyrrolo[2,1-*a*]isoquinolines, highlighting the relevance of the marine natural product Lamellarins. These compounds have shown exceptional cytotoxic activity and have proven to be convincing topoisomerase inhibitors, highlighting their importance in the field of medicinal chemistry. In addition, several studies on the possible mechanisms of action of pyrrolo[2,1-*a*]isoquinolines highlight the intricacies of how these compounds exert their cytotoxic effects and open the door to innovative therapeutic interventions. Their diverse structural features have made them promising candidates for further exploration in drug discovery. In-depth studies of their biological activity have become a fundamental step in the search for new therapeutic agents.

Furthermore, the dynamic overview of synthetic strategies in the total synthesis and molecular diversification of pyrrolo[2,1-*a*]isoquinolines shows the contribution to the expansion of structural diversity and provides valuable insights into structure–activity relationships (SARs). These efforts offer a promising avenue for developing more potent and selective derivatives.

An in-depth study of the various biological and chemical characteristics of pyrrolo[2,1-*a*]isoquinolines highlights the profound synergy between biological chemistry and medicinal chemistry in the search for new pharmaceutical agents. The importance of collaboration between these disciplines cannot be overemphasized, as it catalyzes innovation and scientific progress.

## Author contributions

Leidy J. García. Conceptualization, formal analysis, and writing. Arturo Mendoza Salgado. Conceptualization, supervision,



review, writing and editing. Vladimir V. Kouznetsov. Supervision, review, and editing. Carlos Mario Melendez. Conceptualization, supervision, formal analysis, review, writing and editing.

## Conflicts of interest

The authors declare nonfinancial interests/personal relationships, which may be considered as potential competing interests.

## Acknowledgements

Leidy J. García, Arturo Mendoza Salgado, and Carlos Mario Meléndez are grateful to Universidad del Atlántico and Min-Ciencias (SGR. BPIN 2020000100161).

## References

- 1 C. Bailly, *Mar. Drugs*, 2015, **13**, 1105–1123.
- 2 T. Fukuda, Y. Nanjo, M. Fujimoto, K. Yoshida, Y. Natsui, F. Ishibashi, F. Okazaki, H. To and M. Iwao, *Bioorganic Med. Chem.*, 2019, **27**, 265–277.
- 3 T. Fukuda, F. Ishibashi and M. Iwao, *Lamellarin Alkaloids: Isolation, Synthesis, and Biological Activity*, Elsevier Inc., 1st edn, 2020, vol. 83.
- 4 L. Zheng, T. Gao, Z. Ge, Z. Ma, J. Xu, W. Ding and L. Shen, *Eur. J. Med. Chem.*, 2021, **214**, 113226.
- 5 M. Chittchang, M. Paul Gleeson, P. Ploypradith and S. Ruchirawat, *Eur. J. Med. Chem.*, 2010, **45**, 2165–2172.
- 6 X. C. Huang, X. Xiao, Y. K. Zhang, T. T. Talele, A. A. Salim, Z. S. Chen and R. J. Capon, *Mar. Drugs*, 2014, **12**, 3818–3837.
- 7 F. Plisson, X. C. Huang, H. Zhang, Z. Khalil and R. J. Capon, *Chem.–An Asian J.*, 2012, **7**, 1616–1623.
- 8 J. Kluza, M. A. Gallego, A. Loyens, J. C. Beauvillain, J. M. F. Sousa-Faro, C. Cuevas, P. Marchetti and C. Bailly, *Cancer Res.*, 2006, **66**, 3177–3187.
- 9 V. Colligs, S. P. Hansen, D. Imbri, E. J. Seo, O. Kadioglu, T. Efferth and T. Opatz, *Bioorganic Med. Chem.*, 2017, **25**, 6137–6148.
- 10 H. Fan, J. Peng, M. T. Hamann and J. F. Hu, *Chem. Rev.*, 2008, **108**, 264–287.
- 11 M. D. Matveeva, R. Purgatorio, L. G. Voskressensky and C. D. Altomare, *Future Med. Chem.*, 2019, **11**, 2735–2755.
- 12 A. L. Wang, S. H. Liao, D. H. Hu and D. P. Li, *Complement. Altern. Med.*, 2011, **2011**, 3–8.
- 13 R. J. Andersen, D. J. Faulkner, C. H. He, G. D. Van Duyne and J. Clardy, *J. Am. Chem. Soc.*, 1985, **107**, 5492–5495.
- 14 J. C. Coll, B. F. Bowden and J. C. Coll, *Aust. J. Chem.*, 1993, **46**, 489–501.
- 15 A. R. Quesada, M. D. García Grávalos and J. L. Fernández Puentes, *Br. J. Cancer*, 1996, **74**, 677–682.
- 16 M. V. R. Reddy, D. J. Faulkner, Y. Venkateswarlu and M. R. Rao, *Tetrahedron*, 1997, **53**, 3457–3466.
- 17 J. Ham and H. Kang, *Bull. Korean Chem. Soc.*, 2002, **23**, 205.
- 18 C. Bailly, *Curr. Med. Chem.*, 2004, **4**, 363–378.
- 19 M. Chittchang, P. Batsomboon, S. Ruchirawat and P. Ploypradith, *ChemMedChem*, 2009, **4**, 457–465.
- 20 D. Pla, F. Albericio and M. Álvarez, *MedChemComm*, 2011, **2**, 689–697.
- 21 K. Yoshida, R. Itoyama, M. Yamahira, J. Tanaka, N. Loaëc, O. Lozach, E. Durieu, T. Fukuda, F. Ishibashi, L. Meijer and M. Iwao, *J. Med. Chem.*, 2013, **56**, 7289–7301.
- 22 S. M. Reddy, M. Srinivasulu, N. Satyanarayana, A. K. Kondapi and Y. Venkateswarlu, *Tetrahedron*, 2005, **61**, 9242–9247.
- 23 S. Urban, L. Hobbs, J. Hooper and R. Capon, *Aust. J. Chem.*, 1995, **48**, 1491.
- 24 H. Zhang, M. M. Conte, X. C. Huang, Z. Khalil and R. J. Capon, *Org. Biomol. Chem.*, 2012, **10**, 2656–2663.
- 25 C. Bailly, *Curr. Med. Chem. Agents*, 2005, **4**, 363–378.
- 26 C. Ballot, J. Kluza, A. Martoriati, U. Nyman, P. Formstecher, B. Joseph, C. Bailly and P. Marchetti, *Mol. Cancer Ther.*, 2009, **8**, 3307–3317.
- 27 D. Pla, M. Martí, J. Farrera-Sinfreu, D. Pulido, A. Francesch, P. Calvo, C. Cuevas, M. Royo, R. Aligué, F. Albericio and M. Álvarez, *Bioconjug. Chem.*, 2009, **20**, 1112–1121.
- 28 A. Heim, A. Terpin and W. Steglich, *Angew. Chem., Int. Ed. Engl.*, 1997, **36**, 155–156.
- 29 S. Urban and R. J. Capon, *Aust. J. Chem.*, 1996, **49**, 711–713.
- 30 R. A. Davis, A. R. Carroll, G. K. Pierens and R. J. Quinn, *J. Nat. Prod.*, 1999, **62**, 419–424.
- 31 A. Hamasaki, J. M. Zimpleman, I. Hwang and D. L. Boger, *J. Am. Chem. Soc.*, 2005, **127**, 10767–10770.
- 32 E. Marco, W. Laine, C. Tardy, A. Lansiaux, M. Iwao, F. Ishibashi, C. Bailly and F. Gago, *J. Med. Chem.*, 2005, **48**, 3796–3807.
- 33 N. Fujikawa, T. Ohta, T. Yamaguchi, T. Fukuda, F. Ishibashi and M. Iwao, *Tetrahedron*, 2006, **62**, 594–604.
- 34 M. Facompré, C. Tardy, C. Bal-Mahieu, P. Colson, C. Perez, I. Manzanares, C. Cuevas and C. Bailly, *Cancer Res.*, 2003, **63**, 7392–7399.
- 35 S. Khiati, Y. Seol, K. Agama, I. D. Rosa, S. Agrawal, K. Fesen, H. Zhang, K. C. Neuman and Y. Pommier, *Mol. Pharmacol.*, 2014, **86**, 193–199.
- 36 M. V. R. Reddy, M. R. Rao, D. Rhodes, M. S. T. Hansen, K. Rubins, F. D. Bushman, Y. Venkateswarlu and D. J. Faulkner, *J. Med. Chem.*, 1999, **42**(11), 1901–1907.
- 37 C. P. Ridley, M. V. R. Reddy, G. Rocha, F. D. Bushman and D. J. Faulkner, *Bioorganic Med. Chem.*, 2002, **10**, 3285–3290.
- 38 L. Shen, N. Xie, B. Yang, Y. Hu and Y. Zhang, *Eur. J. Med. Chem.*, 2014, **85**, 807–817.
- 39 D. Skropeta, N. Pastro and A. Zivanovic, *Mar. Drugs*, 2011, **9**, 2131–2154.
- 40 J.-Y. Mérou, C. Neagoie, S. Routier, A. Lansiaux, F. Buron, E. Vedrenne, L. Meijer, B. Baldeyrou, S. Bourg, S. Rosca and O. Lozach, *Eur. J. Med. Chem.*, 2012, **49**, 379–396.
- 41 D. Baunbæk, N. Trinkler, Y. Ferandin, O. Lozach, P. Ploypradith, S. Ruchirawat, F. Ishibashi, M. Iwao and L. Meijer, *Mar. Drugs*, 2008, **6**(4), 514–527.
- 42 A. Theppawong, P. Ploypradith, P. Chuawong, S. Ruchirawat and M. Chittchang, *Chem.–An Asian J.*, 2015, **10**, 2631–2650.



- 43 T. Fukuda, T. Umeki, K. Tokushima, G. Xiang, Y. Yoshida, F. Ishibashi, Y. Oku, N. Nishiya, Y. Uehara and M. Iwao, *Bioorganic Med. Chem.*, 2017, **25**, 6563–6580.
- 44 G. Kroemer, L. Galluzzi and C. Brenner, *Physiol. Rev.*, 2007, **87**, 99–163.
- 45 C. Ballot, J. Kluza, S. Lancel, A. Martoriati, S. M. Hassoun, L. Mortier, J. C. Vienne, G. Briand, P. Formstecher, C. Bailly, R. Nevière and P. Marchetti, *Apoptosis*, 2010, **15**, 769–781.
- 46 F. Ishibashi, *Tetrahedron*, 1997, **53**, 5951–5962.
- 47 D. L. Boger, C. W. Boyce, M. A. Labroli, C. A. Schon and Q. Jin, *J. Am. Chem. Soc.*, 1999, **121**, 54–62.
- 48 Q. Li, J. Jiang, A. Fan, Y. Cui and Y. Jia, *Org. Lett.*, 2011, **13**, 312–315.
- 49 D. M. Lade, A. B. Pawar, P. S. Mainkar and S. Chandrasekhar, *J. Org. Chem.*, 2017, **82**, 4998–5004.
- 50 V. C. Colligs, C. Dialer and T. Opatz, *Eur. J. Org. Chem.*, 2018, **2018**, 4064–4070.
- 51 D. Imbri, J. Tauber and T. Opatz, *Chem.–A Eur. J.*, 2013, **19**, 15080–15083.
- 52 H. J. Shirley, M. Koyioni, F. Muncan and T. J. Donohoe, *Chem. Sci.*, 2019, **10**, 4334–4338.
- 53 M. Leonardi, M. Villacampa and J. C. Menéndez, *J. Org. Chem.*, 2017, **82**, 2570–2578.
- 54 M. Lautens and K. Yamamoto, *Synfacts*, 2016, **12**, 506.
- 55 J.-C. Castillo, A. Tigreros, Y. Coquerel, J. Rodríguez, M. A. Macías and J. Portilla, *ACS Omega*, 2019, **4**, 17326–17339.
- 56 K. Zaman, F. Rahim, M. Taha, A. Wadood, S. A. A. Shah, Q. U. Ahmed and Z. A. Zakaria, *Sci. Rep.*, 2019, **9**, 16015.
- 57 C. E. Puerto Galvis and V. V. Kouznetsov, *Studies in Natural products Chemistry*, ed. H. E. Atta-ur-Rahman, 2018, vol. 56, pp. 1–51.
- 58 R. Gujjarappa, N. Vodnala and C. C. Malakar, *Adv. Synth. Catal.*, 2020, **362**, 4896–4990.
- 59 L. Zhang, Y. Song, J. Huang, J. Liu, W. Zhu, Y. Zhou, J. Lv, C. Zheng and J. Zhu, *Int. J. Mol. Sci.*, 2015, **16**, 10173–10184.
- 60 E. Awuah and A. Capretta, *J. Org. Chem.*, 2010, **75**, 5627–5634.
- 61 Z. Shi, D. C. Koester, M. Bouladakis-Arapinis and F. Glorius, *J. Am. Chem. Soc.*, 2013, **135**, 12204–12207.
- 62 X. Yang, J. Jie, H. Li and M. Piao, *RSC Adv.*, 2016, **6**, 57371–57374.
- 63 S. Xing, J. Ren, K. Wang, H. Cui, H. Yan and W. Li, *Adv. Synth. Catal.*, 2016, **358**, 532–538.
- 64 Y. Long, Z. She, X. Liu and Y. Chen, *J. Org. Chem.*, 2013, **78**(6), 2579–2588.
- 65 M. Arambasic, J. F. Hooper and M. C. Willis, *Org. Lett.*, 2013, **15**, 5162–5165.
- 66 L. Zheng, J. Ju, Y. Bin and R. Hua, *J. Org. Chem.*, 2012, **77**, 5794–5800.
- 67 F. A.-M. Seoane-Carabel Lorena, L. A. Sarandeses and J. P. Sestelo, *Synthesis*, 2022, **55**, 1714–1723.
- 68 X.-H. Chen, Y.-Y. Pan, W.-X. Wang and H.-L. Cui, *Synlett*, 2022, **33**(16), 1645–1654.
- 69 C. Mohan, R. B. Krishna, S. T. Sivanandan and I. Ibnusaud, *Eur. J. Org. Chem.*, 2021, **2021**, 4911–4926.
- 70 X.-H. Chen, X. Xiao, J.-Q. Li, W.-Z. Li and H.-L. Cui, *Tetrahedron Lett.*, 2021, **87**, 153548.
- 71 Z.-H. Shang, X.-J. Zhang, Y.-M. Li, R.-X. Wu, H.-R. Zhang, L.-Y. Qin, X. Ni, Y. Yan, A.-X. Wu and Y.-P. Zhu, *J. Org. Chem.*, 2021, **86**, 15733–15742.
- 72 G. S. Astakhov, R. R. Shigaev, T. N. Borisova, A. A. Ershova, A. A. Titov, A. V. Varlamov, L. G. Voskressensky and M. D. Matveeva, *Mol. Divers.*, 2021, **25**, 2441–2446.
- 73 Z. Li, N. Xu, N. Guo, Y. Zhou, L. Lin and X. Feng, *Chem.–A Eur. J.*, 2021, **27**, 14841–14845.
- 74 R. S. Rao, A. Sahani, S. H. Ali, S. Pradhan and C. R. Ramanathan, *J. Heterocycl. Chem.*, 2021, **58**, 1415–1428.
- 75 S. A. Babu, A. R. Rajalekshmi, P. R. Nitha, V. K. Omanakuttan, P. Rahul, S. Varughese and J. John, *Org. Biomol. Chem.*, 2021, **19**, 1807–1817.
- 76 Y.-W. Xu, J. Wang, G. Wang and L. Zhen, *J. Org. Chem.*, 2021, **86**, 91–102.
- 77 M. Koohgard and M. Hosseini-Sarvari, *J. Photochem. Photobiol., A*, 2021, **404**, 112877.
- 78 K. S. Mandrekar and S. G. Tilve, *RSC Adv.*, 2022, **12**, 17701–17705.
- 79 A. R. Miftakhova, M. B. Sidakov, T. N. Borisova, V. V. Ilyushenkova, A. N. Fakhrutdinov, E. A. Sorokina, A. V. Varlamov and L. G. Voskressensky, *Tetrahedron Lett.*, 2022, **103**, 153991.
- 80 D. Yu, Y. Liu and C.-M. Che, *Org. Chem. Front.*, 2022, **9**, 2779–2785.
- 81 A. Toumi, S. Boudriga, K. Hamden, I. Daoud, M. Askri, A. Soldera, J.-F. Lohier, C. Strohmman, L. Brieger and M. Knorr, *J. Org. Chem.*, 2021, **86**, 13420–13445.
- 82 S. Boudriga, S. Haddad, M. Askri, A. Soldera, M. Knorr, C. Strohmman and C. Golz, *RSC Adv.*, 2019, **9**, 11082–11091.
- 83 N. V. M. Thomas, S. S. Leena and A. Deepthi, *Synthesis*, 2022, **54**, 2885–2893.
- 84 D. J. Boruah, D. Kathirvelan, S. Borra, R. A. Maurya and P. Yuvaraj, *New J. Chem.*, 2022, **46**, 792–797.
- 85 Y. Huang, Y.-X. Huang, J. Sun and C.-G. Yan, *RSC Adv.*, 2018, **8**, 23990–23995.
- 86 R. M. Chávez-Santos, P. E. Reyes-Gutiérrez, R. O. Torres-Ochoa, M. T. Ramírez-Apan and R. Martínez, *Chem. Pharm. Bull.*, 2017, **65**, 973–981.
- 87 P. E. Reyes-Gutiérrez, J. R. Camacho, M. T. Ramírez-Apan, Y. M. Osornio and R. Martínez, *Org. Biomol. Chem.*, 2010, **8**, 4374–4382.
- 88 A. A. Nevskaya, M. D. Matveeva, T. N. Borisova, M. Niso, N. A. Colabufo, A. Boccarelli, R. Purgatorio, M. de Candia, S. Cellamare, L. G. Voskressensky and C. D. Altomare, *ChemMedChem*, 2018, **13**, 1588–1596.
- 89 A. A. Nevskaya, L. V. Anikina, R. Purgatorio, M. Catto, O. Nicolotti, M. de Candia, L. Pisani, T. N. Borisova, A. R. Miftakhova, A. V. Varlamov, E. Y. Nevskaya, R. S. Borisov, L. G. Voskressensky and C. D. Altomare, *Molecules*, 2021, **26**, 259.
- 90 S. Kakhki, S. Shahosseini and A. Zarghi, *Iran. J. Pharm. Res.*, 2016, **15**, 743–751.

